This inventor holds 11 USPTO granted patents and 1 EPO patent. Top assignees: University of California, Mmc/gatx Partnership No. 1. Active years: 1986-2010.
Company Filing History:
Years Active: 1986-2010
Title: Innovations of Curtis A. Gleason: A Pioneer in Neural Transmission Technologies
Introduction: Curtis A. Gleason, an accomplished inventor based in Palo Alto, California, has made significant contributions to the field of neural transmission. With a total of 11 patents to his name, his work has paved the way for advancements in medical technologies that address chronic pain and bladder control issues. Gleason's innovative approach through electrical stimulation techniques underscores the intersection of engineering and medicine in modern healthcare.
Latest Patents: Among his latest innovations, Gleason has developed two noteworthy patents. The first is a method and system designed for selectively inhibiting the neural transmission of somatic fibers. This method utilizes alternate phase rectangular electrical pulses to selectively inhibit somatic nerve fibers in a mixed nerve. This technology proves invaluable in treating chronic pain, managing spastic muscles, and facilitating sensory and motor control of the bladder. An electrical pulse generator is used to apply alternating high-frequency, low-amplitude pulses to inhibit somatic nerves, followed by low-frequency, high-amplitude pulses to stimulate autonomic nerve fibers, allowing controlled voiding of the bladder and bowel.
The second patent focuses on similar methodologies for selective control of bladder function. It implements the same principles to enhance medical treatment options and quality of life for patients dealing with related medical conditions.
Career Highlights: Curtis A. Gleason's professional journey includes impactful tenures at notable institutions, such as the University of California. His work there has been instrumental in bridging academic research with practical medical applications, showcasing the importance of collaboration between universities and industry in fostering innovation. Additionally, Gleason has been associated with the MMC/GATX Partnership No. 1, where his contributions further enhanced the organization's technological capabilities.
Collaborations: Throughout his career, Gleason has had the privilege of collaborating with esteemed colleagues, including Emil A. Tanagho and Tom F. Lue. These collaborations have not only enriched his work but have also facilitated the exchange of ideas and advancements in the field of neurotechnology.
Conclusion: Curtis A. Gleason's inventive spirit and dedication to advancing neural transmission technologies have qualified him as a noteworthy figure in his field. With his unique methods for addressing complex medical challenges, he continues to inspire future innovations that improve patient outcomes and enhance quality of life through groundbreaking technologies. His patents are a testament to his commitment to merging science and healthcare, proving that the potential for innovation in medicine is vast and ever-evolving.